Company Name: ZS Pharma Inc.
Location: Ft. Worth, Texas
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Industry: Pharmaceuticals
Solution/Product: ZS-9, an oral sorbent technology platform that will first be applied to removing toxins in patients suffering from hyperkalemia, or high levels of potassium in the blood, as a result of kidney and liver disease and related conditions.
Money Raised: $5.3 million since November
How will it be used: First round of clinical trials to test the drug in acute hyperkalemia, according to the Dallas Business Journal. President and CEO Al Guillem wasn’t immediately available to comment.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Investors: The filing lists Marc Ostro, of Devon Park Bioventures, and Robert Truitt, of Ash Access Technology, among the company’s board of directors. In 2010, ZS Pharma received $2 million from the state’s Emerging Technology Fund.
Competitors: Artificial kidneys like the ones being developed by researchers at UCSF, CreatiVasc Medical; Blood Purification Technologies.
